Effect of penicillamine and zinc on iron metabolism in Wilson's disease

Scand J Gastroenterol. 2007 Dec;42(12):1495-500. doi: 10.1080/00365520701514495.

Abstract

Objective: The physiology of iron metabolism in Wilson's disease is largely unknown, and there is a paucity of data on the real presence and progression of iron accumulation. The purpose of this study was to assess the iron metabolism parameters, including hepatic iron concentration, in follow-up liver biopsies and serum, and urinary pro-hepcidin.

Material and methods: Twenty-three Wilson's disease patients undergoing long-term treatment were enrolled in the study.

Results: Hepatic iron content was significantly increased in penicillamine-treated patients compared with zinc-treated patients. Serum and urinary pro-hepcidin concentrations were significantly higher in Wilson's disease patients than in healthy volunteers, despite a normal biochemical pattern of iron metabolism.

Conclusions: Long-term penicillamine treatment seems to be responsible for a more marked iron accumulation in the liver. This observation may justify a revision of long-term Wilson's disease treatment modalities with penicillamine. The finding that serum and urinary pro-hepcidin is significantly increased in Wilson's disease patients compared with healthy volunteers suggests a role for hepcidin in iron metabolism in Wilson's disease, but this needs to be confirmed by a study of hepatic hepcidin expression in these patients.

MeSH terms

  • Adolescent
  • Adult
  • Biopsy
  • Chelating Agents / therapeutic use*
  • Female
  • Hepatolenticular Degeneration / drug therapy*
  • Hepatolenticular Degeneration / metabolism
  • Humans
  • Iron / metabolism*
  • Male
  • Middle Aged
  • Penicillamine / therapeutic use*
  • Statistics, Nonparametric
  • Treatment Outcome
  • Zinc Sulfate / therapeutic use*

Substances

  • Chelating Agents
  • Zinc Sulfate
  • Iron
  • Penicillamine